Loading...
In this manufacturer-sponsored, open-label, international trial, researchers compared the effectiveness and safety of enoxaparin (low-molecular-weight heparin) and of unfractionated heparin in reducing the overall number of venous-thromboembolism (VTE) events after acute ischemic stroke. The authors randomized 1762 patients within 48 hours of an acute ischemic stroke to receive either enoxaparin (40 mg once daily) or unfractionated heparin (5000 U every 12 hours) for a mean of 10 days. Patients underwent ultrasound, venography, or both. Pulmonary embolism, if suspected, was evaluated by ventilation perfusion scan, helical CT, or angiography.
The analysis included 76% of the patients. Compared with unfractionated heparin, enoxaparin conferred…